Assessing the eligibility of a breast cancer patient for genomic testing - European Medical Journal

Assessing the eligibility of a breast cancer patient for genomic testing

Oncology

Genomic tests, such as the Oncotype DX® Breast Cancer Assay, provide results that quantify recurrence risk and identify patients who are likely or unlikely to benefit from adjuvant chemotherapy. At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph Gligorov, MD, PhD, of Sorbonne Université, Paris, France, outlines the approaches for effectively communicating personalised genomic disease-risk information to breast cancer patients.

This content is supported by Genomic Health, Inc.

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?

Keep your finger on the pulse

Join Now

Elevating the Quality of Healthcare Globally

>